What is the price of the Lao version of pemetinib? What are the differences compared with the original drug?

The Lao version of pemigatinib has significant advantages over the original drug in terms of price. According to market information, the generic pemetinib drug produced by Lucius Pharmaceuticals in Laos has a specification of 4.5mg*14 tablets and is priced at more than 700 yuan per box. The original drug is priced at as high as 20,000-50,000 yuan per box in the domestic market, and the price in overseas markets may even reach more than 70,000 yuan. It can be seen that the price of the Lao version of pemetinib is only a fraction of the original drug, making the drug more affordable for more patients and improving the accessibility of treatment.

In terms of ingredients and efficacy, the Lao version of pemetinib is basically the same as the original drug. During the production process, generic drugs usually refer to the chemical composition and formula of the original drug to ensure their bioequivalence, that is, their absorption, metabolism and efficacy in the body are similar to those of the original drug. However, because generic drugs may be slightly different from original drugs in terms of production processes, excipients, dissolution rates, etc., some patients may have subtle differences in individual tolerance or drug efficacy experience. Therefore, when choosing the Lao version of pemetinib, patients should consult their doctor to ensure that its treatment effect meets their needs.

From the perspective of the applicable population, both the original drug and the Lao version of pemetinib are mainly used to treat patients with cholangiocarcinoma carrying FGFR2 fusions or rearrangements. Pemetinib, as a selective FGFR inhibitor, can effectively block the abnormal activation of the FGFR pathway and inhibit the growth of tumor cells. For patients with limited financial conditions, the Lao version of pemetinib provides a more cost-effective treatment option, helping patients obtain relatively high-quality treatment options at a lower cost.
Overall, the Lao version of pemetinib has become an alternative choice for some patients due to its lower price. Although generic drugs have certain feasibility in clinical use, there may be certain gaps between them and original drugs in terms of quality supervision and production technology. Therefore, when choosing generic drugs, patients are advised to consult a professional doctor first and make a reasonable choice based on their own financial situation and treatment needs. No matter which version of pemetinib is used, patients need to take the medication regularly under the guidance of a doctor to ensure the safety and effectiveness of the treatment.
Reference: https://go.drugbank.com/drugs/DB15102